热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　4月29日消息，港股生物技术板块多股大涨，截至发稿，药明康德、科伦博泰生物涨近6%，创胜集团、来凯医药、乐普生物涨超5%，云顶新耀、中国抗体、康方生物涨超4%。

　　消息面上，国投证券发布研报称，全球创新药投融资环境有所复苏，多肽、ADC等细分领域创新研发蓬勃兴起，加速推动CXO行业景气度上行，研发生产外包需求有望逐步改善。目前CXO上市公司相关订单开始逐步改善且产能处于行业领先地位，看好CXO上市公司业绩边际改善。

　　个股方面，药明康德公布2025年第一季度业绩，营业收入约96.55亿元，同比增长20.96%；归属于上市公司股东的净利润约36.72亿元，同比增长89.06%。截至2025年3月末，公司持续经营业务在手订单人民币523.3亿元，同比增长47.1%。

　　4月25日，科伦博泰生物股东将股票存入中国证券登记结算香港，存仓市值78.35亿港元，占比19.34%。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.